CYP2C9 and lymphopenia: This explains why some subjects started siponimod treatment without a CYP2C9 genotype at baseline, the potentially insufficient washout time from prior therapies and the fact that treatment was started despite the presence of some degree of lymphopenia in some patients, and the high variability in the timing of the complete blood count (CBC) analyses.